BCAL DIAGNOSTICS LIMITED

ASX: BDX

Sector: Sector:Health Care
Industry group: Industry:Pharmaceuticals, Biotechnology & Life Sciences

BDX News & Analysis

BDXHealth CareSubstantial Holders26 Aug 202626 August 2026· 2 min read

BCAL Diagnostics (ASX: BDX) Raises Genetic Signatures Stake to 18.46%

BCAL Diagnostics has paid $1.5 million to lift its Genetic Signatures holding to 18.46%. The investment broadens its strategic exposure beyond cancer diagnostics.

Latest BDX ASX Announcements

1 Oct 2026 · 6:23 pmSubstantial Holders
Change in substantial holding
1 Oct 20266:23 pmChange in substantial holdingSubstantial Holders
30 Sept 2026 · 8:48 amCompany Update
BREASTESTplus 2 clinically validated
30 Sept 20268:48 amBREASTESTplus 2 clinically validatedCompany Update
23 Sept 2026 · 10:43 amCompany Update
BCAL Introduces Avantect Multi-Cancer Early Detection Test
23 Sept 202610:43 amBCAL Introduces Avantect Multi-Cancer Early Detection TestCompany Update
18 Sept 2026 · 8:22 amMeetings & Governance
Letter to Shareholders re Annual General Meeting
18 Sept 20268:22 amLetter to Shareholders re Annual General MeetingMeetings & Governance
18 Sept 2026 · 8:22 amMeetings & Governance
Notice of Annual General Meeting/Proxy Form
18 Sept 20268:22 amNotice of Annual General Meeting/Proxy FormMeetings & Governance
10 Sept 2026 · 1:19 pmOther
Clarification of BCAL's Position in Relation to GSS
10 Sept 20261:19 pmClarification of BCAL's Position in Relation to GSSOther
3 Sept 2026 · 12:40 pmCompany Administration
BCAL Seeks Board Change at Genetic Signatures
3 Sept 202612:40 pmBCAL Seeks Board Change at Genetic SignaturesCompany Administration
3 Sept 2026 · 11:47 amPresentations
Investor Presentation September 2026
3 Sept 202611:47 amInvestor Presentation September 2026Presentations
31 Aug 2026 · 2:30 pmPresentations
Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
31 Aug 20262:30 pmMeet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PMPresentations
28 Aug 2026 · 3:46 pmCompany Administration
Appendix 4G and Corporate Governance Statement
28 Aug 20263:46 pmAppendix 4G and Corporate Governance StatementCompany Administration
28 Aug 2026 · 3:44 pmFinancial Results
Appendix 4E and Annual Report to shareholders
28 Aug 20263:44 pmAppendix 4E and Annual Report to shareholdersFinancial Results
26 Aug 2026 · 8:57 amSubstantial Holders
BCAL Takes Interest in Genetic Signatures to 18.46%
26 Aug 20268:57 amBCAL Takes Interest in Genetic Signatures to 18.46%Substantial Holders
26 Aug 2026 · 8:35 amOther
Change in Substantial Shareholder Notice for GSS
26 Aug 20268:35 amChange in Substantial Shareholder Notice for GSSOther
25 Aug 2026 · 6:53 pmSecurities Administration
Notification regarding unquoted securities - BDX
25 Aug 20266:53 pmNotification regarding unquoted securities - BDXSecurities Administration
21 Aug 2026 · 6:27 pmSecurities Administration
Notification regarding unquoted securities - BDX
21 Aug 20266:27 pmNotification regarding unquoted securities - BDXSecurities Administration

View complete BDX announcement history →

BCAL DIAGNOSTICS LIMITED

BDX Share Price

BDX News & Analysis

BCAL Diagnostics (ASX: BDX) Raises Genetic Signatures Stake to 18.46%

Latest BDX ASX Announcements